• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability

    Machining & Laser Processing Have Huge Parts to Play in Medtech Manufacturing

    Medtech R&D Teams Must Be Creative & Resilient to Survive

    Struggling Suppliers in Electronics Manufacturing Services (EMS)

    Deep (Brain) Thoughts with Medtronic's Neuromodulation President
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Konica Minolta Introduces Mobile X-Ray Systems to Latin America

    NIH MedTech Program Aims to Develop Neurological Treatment Tech

    Formula Plastics Appoints Bill Gerard as President

    First Patient Undergoes Kidney Stone Removal Using MONARCH Platform

    Michael Duqette Named COO at Producto Group
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability

    Machining & Laser Processing Have Huge Parts to Play in Medtech Manufacturing

    Medtech R&D Teams Must Be Creative & Resilient to Survive

    Struggling Suppliers in Electronics Manufacturing Services (EMS)

    Deep (Brain) Thoughts with Medtronic's Neuromodulation President
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Deducing the Dual Reality of Elizabeth Holmes

    The Return of the AdvaMed MedTech Conference…Live!

    Material Matters: New Materials Call for New Thinking

    5 Ways to Maintain a Talent-Centric Mindset, Even During Economic Uncertainty

    The Changing Face of UK Medical Device Regulations: Most Recent Update
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Paragon Medical

    Arthur G. Russell Co. Inc., The

    JBC Technologies

    Medbio LLC

    Halkey-Roberts Corporation
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Onshoring Medical Device Manufacturing Can Strengthen Supply Chains

    How Artificial Intelligence Can Combat Key Issues Impacting Healthcare

    Why Advanced Sensors Are Crucial Within Medical Pumps

    How Artificial Intelligence Could Help Prevent 80% of Chronic Diseases

    4 Ways to Use Injection Molding in Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Paragon Medical

    Arthur G. Russell Co. Inc., The

    JBC Technologies

    Medbio LLC

    Halkey-Roberts Corporation
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Top30

    4. Abbott

    ...

    Related Content
    • FDA OKs Abbott's Next-Gen MitraClip
    • FDA Approves Abbott's Alinity s System
    • Abbott Launches Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
    • Care Points: The Current State of Point of Care Diagnostics
    • Abbott & NIH Team Up to Advance Neuroscience Research
    07.30.19
    AT A GLANCE
    Rank: #4 (Last year: #6)
    $18.93 Billion ($30.6B total)
    Prior Fiscal: $16.2 Billion
    Percentage Change: +17%
    No. of Employees: 103,000
    Global Headquarters: Abbott Park, Ill.

    KEY EXECUTIVES
    Miles D. White, Chairman and CEO
    Robert B. Ford, President and COO
    Hubert L. Allen, Exec. VP, General Counsel and Secretary
    Brian J. Blaser, Exec. VP, Diagnostics Products
    John M. Capek, Ph.D., Exec. VP, Ventures
    Stephen R. Fussell, Exec. VP, Human Resources
    John F. Ginascol, Exec. VP, Core Diagnostics
    Brian B. Yoor, Exec. VP, Finance and CFO
    Chuck Brynelsen, Sr. VP, Abbott Vascular
    Jaime Contreras, Sr. VP, Core Laboratory Diagnostics, Commercial Operations
    Robert Funck, Sr. VP, Finance and Controller
    Corlis D. Murray, Sr. VP, Quality Assurance, Regulatory and Engineering Services
    Michael J. Pederson, Sr. VP, Cardiac Arrhythmias and Heart Failure
    Christopher J. Scoggins, Sr. VP, Rapid Diagnostics
    Jared L. Watkin, Sr. VP, Diabetes Care
    Randel Woodgrift, Sr. VP, Cardiac Rhythm Management

    In a January 2018 piece about the firm and its leader, Forbes senior contributor Bruce Japsen was right on the money when he stated Abbott’s CEO, Miles White, “may be setting the diversified healthcare company up for a calm year of paying down debt and investing in research and operational performance.” After experiencing back-to-back headlines-filled years in 2016 and 2017, dominated by the two multi-billion dollar acquisitions of St. Jude and Alere, as well as the subsequent ups and downs that came with both transactions—cybersecurity and “hacking” concerns with St. Jude devices, and ethical and financial issues with Alere—it’s no wonder 2018 was significantly quieter in comparison.

    At the time of the Forbes article, Abbott’s debt load had recently been reduced by $4 billion from $28 billion, which represented the largest in the firm’s 130-year history (a result of the two major deals in the years prior). White expected to pay down another $4 billion before the end of 2018, noting that as a top priority. According to the firm’s 2018 annual report, the company exceeded that goal by approximately $700 million.

    Without looking to conduct market-leading M&A transactions in 2018, Abbott was able to focus on organic growth through product launches and innovation. Although the firm wasn’t making much noise in business and financial headlines, that by no means meant it was operating under the radar during the year. Just ask now 4-year-old Sadie Rutenberg of Seattle, Wash., how Abbott has made an impact.

    Sadie, the “cover model” for the firm’s 2018 annual report, was a participant in a clinical trial for the Masters HP 15-mm rotatable mechanical heart valve, becoming the first child in the U.S. to receive the Abbott device. The dime-sized implant—the world’s smallest mechanical heart valve for pediatric patients with heart defects—received FDA approval in March 2018 and represented just one way the organization had a substantial effect during the year.

    “There’s an urgent need for the smallest babies and children who need a suitable replacement valve in order to survive,” Michael Dale, vice president of Abbott’s structural heart business, said in a news release announcing the approval. “Abbott’s new mechanical pediatric heart valve is a life-changing technology for the smallest pediatric patients, giving them a better chance at a long, healthy life with a fully functioning heart.”

    In fact, the company claims in the U.S. alone, heart defects affect nearly 1 percent of births each year (about 40,000). Those involving a poorly functioning valve gained a new option with the approval.

    The pediatric valve joined a family of products produced by Abbott to treat an array of heart-related conditions, housed within the firm’s Cardiovascular and Neuromodulation business. The unit, bolstered substantially by the St. Jude acquisition, contributed $9.44 billion to the organization’s 2018 $30.58 billion sales total as the largest of all of Abbott’s four major businesses.

    The segment is comprised of six divisions, led in 2018 by the Vascular portion, which contributed $2.9 billion to the sales total ($1.1B from U.S. and $1.8B from international).

    Following that was Rhythm Management, Electrophysiology, and Structural Heart, offering $2.1 billion ($1.0B U.S.; $1.1B intl.), $1.7 billion ($764M U.S.; $904M intl.), and $1.2 billion ($488M U.S.; $751M intl.) respectively. Only two portions were under $1 billion in sales—Neuromodulation at $864 million ($690M U.S. and $174M intl.) and Heart Failure at $646 million ($467M U.S. and $179 intl.). Perhaps not so coincidently, those two units were also the only ones of the six where U.S. sales exceeded those from abroad. Further, five of the six units saw growth over the prior fiscal year, which was $8.9 billion for the entire business in 2017, with Rhythm Management as the lone exception.

    Although perhaps most newsworthy, the pediatric valve was not the only new product from Abbott’s Cardiovascular and Neuromodulation business to gain attention during its last fiscal year. Among other notable product news was:

    FDA approval for magnetic resonance-conditional labeling for the Quadra Assura MP cardiac resynchronization therapy defibrillator and Fortify Assura implantable cardioverter defibrillator. The approvals follow with similar decisions by the regulatory agency regarding MRI-ready implantable cardiac solutions sold by Abbott. In addition, both the Fortify Assura and Quadra Assura MP include the company’s suite of TailoredTherapy features, which are designed to provide physicians additional flexibility and control in how they deliver therapy to treat their patients’ cardiac arrhythmias and congestive heart failure. Finally, the Quadra Assura MP also offers MultiPoint Pacing and SyncAV technology to provide additional options for patients who are not responsive to traditional cardiac resynchronization therapy.

    The Advisor HD Grid Mapping Catheter with Sensor Enabled technology gained FDA clearance in May. The device’s design allows physicians to capture and analyze data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue.

    The DRG Invisible Trial System, which had secured both U.S. FDA approval and a European CE mark, was launched in November. The technology leverages Abbott’s dorsal root ganglion (DRG) stimulation technology, providing an opportunity for patients to try a non-opioid pain therapy before actually getting an implantable device. If the DRG therapy works for a patient, they would then have the company’s Proclaim DRG system implanted.

    The XIENCE Sierra, the latest in the company’s line of everolimus-eluting coronary stents, received FDA approval last May. Design and technology advances in this generation of XIENCE provide features specifically designed for the treatment of complex blockages that now account for up to 70 percent of cases, according to Abbott. Those design innovations include a thinner profile, increased flexibility, longer lengths, and small diameters.

    An EU CE mark was received and FDA granted approval of the firm’s next-generation version of the MitraClip heart valve repair device used to repair a leaky mitral valve without open-heart surgery. This offering provides advanced steering, navigation, and positioning capabilities, making it easier to use in difficult anatomies.

    In October, the HeartMate 3 Left Ventricular Assist Device (LVAD) gained FDA approval as a destination therapy for people living with advanced heart failure, enabling the system to be used for patients not eligible for a transplant who will live with their device for the rest of their lives. While reducing the size of the LVAD, the company also employed Full MagLev (fully magnetically-levitated) Flow, which reduces trauma to the blood passing through the pump while improving flow.

    Abbott’s Diagnostics business came in second in overall sales contributions at $7.5 billion, but reflected the greatest dollar increase over prior year, which was $5.6 billion in 2017. While all four units of Diagnostics saw increases in sales over the prior year, two were almost flat while a third accounted for almost the entirety of the rise. Core Laboratory enjoyed a modest increase between 2017’s $4.1 billion in sales to 2018’s $4.4 billion ($985M U.S.; $3.4B intl.). Point of Care and Molecular, virtually flat, had sales of $553M and $484M in 2018 respectively. Experiencing a huge bump in contribution, Rapid Diagnostics went from $540 million in 2017 to $2.1 billion in 2018 ($1.1B U.S.; $924M intl.). Undoubtedly, the full integration of Alere and its product line into the fold was the most significant factor in the increase year-over-year.

    Similar to the Cardiovascular and Neuromodulation business, Diagnostics enjoyed positive news of its own with regard to its product offerings.

    Most notable among the highlights was the CE mark awarded for the first troponin test to enable a better prediction of the chances for a heart attack or other cardiac event potentially months to years in advance in people who otherwise appear healthy. The test enables doctors to alter how they identify those at risk for developing heart disease because the diagnostic test uses a biomarker specific to the heart. With this added information, doctors can help ensure the correct treatment is given to people at high risk and prevent unnecessary testing, medication, and costs for lower-risk patients.

    Across the pond, the FDA cleared Abbott’s next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. According to the company, at the time of the clearance announcement, the Influenza A & B 2 assay offers the fastest point-of-care molecular detection and differentiation of influenza A and B virus available—13 minutes or less, with early call out of positive results in as little as five minutes. The Strep A 2 provides molecular detection of Group A Streptococcus bacterial nucleic acid more than twice as rapidly as other available molecular tests—in six minutes or less, with call out of positive results as early as two minutes.

    The company also announced the first viral load point-of-care test designed to provide healthcare professionals, especially in remote and underserved communities, with a fast, accurate, and easy-to-use test to manage HIV. By providing viral load test results in less than 70 minutes, this life-changing technology allows patients to get tested and treated in the same visit.

    A CE mark was received for the Alinity h-series integrated system for hematology testing. The system integrates the Alinity hq with the Alinity hs slide maker and stainer module into a combined solution. The solution is 20 percent faster per m2 than other currently available integrated hematology systems, according to Abbott, with a throughput of 133 complete blood counts (CBCs) per m2.

    Also in 2018, the company launched its Afinion 2 analyzer in the U.S. for diabetes management. The analyzer is a compact rapid, multi-assay platform that streamlines and simplifies the delivery of actionable, accurate measurements of hemoglobin A1c (HbA1c) and albumin to creatinine ratio (ACR) results at the point of care. The system arms healthcare professionals with the information needed to make fast and accurate medical decisions—three minutes for HbA1c and five minutes for ACR—enabling healthcare professionals to dedicate more time to counseling diabetes patients within a single office visit.

    Speaking of diabetes, Abbott reports on its offerings for this space as “other” in its annual report, although it’s a significant segment of the company. The products out of this portion led to just shy of $2 billion in sales, with a 25/75 percent ratio U.S./international ($493 million versus $1.5 billion). The group saw a substantial rise over 2017, which had the contribution from this segment at $1.65 billion.

    Abbott’s diabetes focus is centered around its Freestyle Libre product, which was the focus of several notable headlines in 2018. Making the most waves was the announcement of its app for the iPhone that enables users to access glucose data directly from their Apple smartphone. This capability eliminated the need for users to carry a separate reader device. While the app had been available for Android users since 2015, it had just been released for the iPhone.

    Also of significance was the announcement of the Freestyle Libre being made available to Medicare patients. The factory-calibrated system is the only CGM system recognized by Medicare that requires no user calibration whatsoever (either by fingerstick or manual data entry) at the time of the company’s announcement. The system also does not require the need for routine fingersticks and allows for patients to dose insulin based on the system’s results. 
    Related Searches
    • cardiac
    • president
    • implantable
    • stents
    Suggested For You
    FDA OKs Abbott FDA OKs Abbott's Next-Gen MitraClip
    FDA Approves Abbott FDA Approves Abbott's Alinity s System
    Abbott Launches Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes Abbott Launches Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
    Care Points: The Current State of Point of Care Diagnostics Care Points: The Current State of Point of Care Diagnostics
    Abbott & NIH Team Up to Advance Neuroscience Research Abbott & NIH Team Up to Advance Neuroscience Research
    Abbott Launches Next Gen of the World’s First Smartphone-Compatible Implantable Heart Monitor Abbott Launches Next Gen of the World’s First Smartphone-Compatible Implantable Heart Monitor
    Abbott, DoD, and TRACK-TBI Partner to Study PoC Test for Concussions Abbott, DoD, and TRACK-TBI Partner to Study PoC Test for Concussions
    Premier Research Names New Medical Device Research and Regulatory Process Experts Premier Research Names New Medical Device Research and Regulatory Process Experts
    Late-Breaking Analyses from Landmark COAPT Trial Show Benefits of Abbott Late-Breaking Analyses from Landmark COAPT Trial Show Benefits of Abbott's MitraClip
    Abbott Abbott's Alinity m Diagnostics System and Assays Gain CE Mark
    Study: CardioMEMS Sensor Reliably Safe, Cuts Hospitalizations by More than Half Study: CardioMEMS Sensor Reliably Safe, Cuts Hospitalizations by More than Half
    FDA Approves Expanded Indication for Abbott FDA Approves Expanded Indication for Abbott's MitraClip
    Medical Device Incubator CEO Appointed to PQ Bypass Board of Directors Medical Device Incubator CEO Appointed to PQ Bypass Board of Directors
    Abbott Launches Reformulated BinaxNOW Rapid Influenza Test Abbott Launches Reformulated BinaxNOW Rapid Influenza Test

    Related Breaking News

    • Cardiovascular | Surgical
      FDA OKs Abbott

      FDA OKs Abbott's Next-Gen MitraClip

      MitraClip G4 includes new clip sizes and an enhanced leaflet grasping feature.
      Abbott Laboratories 07.16.19

    • Diagnostics
      FDA Approves Abbott

      FDA Approves Abbott's Alinity s System

      Alinity s System will screen the U.S. blood and plasma supply faster and more efficiently while maintaining highest levels of accuracy.
      Abbott Laboratories 07.11.19

    • Abbott Launches Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

      Abbott Launches Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

      The Afinion HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation.
      PRNewswire 06.17.19


    • Diagnostics | Materials
      Care Points: The Current State of Point of Care Diagnostics

      Care Points: The Current State of Point of Care Diagnostics

      Speed, convenience, and cost are driving innovation in the global point-of-care market.
      Michael Barbella, Managing Editor 06.13.19

    • Neurological
      Abbott & NIH Team Up to Advance Neuroscience Research

      Abbott & NIH Team Up to Advance Neuroscience Research

      Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies.
      Abbott Laboratories 05.15.19

    Loading, Please Wait..

    Trending
    • MO SCI Acquires Assets Of 3M’s Advanced Materials Business
    • CGM Devices Could Become Main Glucose Monitoring Solution In U.S.
    • Positive Long-Term Prospects For Japanese Diabetes Care Market
    • The Future Of Biomedical Engineering Advancements
    • First Patient Undergoes Kidney Stone Removal Using MONARCH Platform
    Breaking News
    • Konica Minolta Introduces Mobile X-Ray Systems to Latin America
    • NIH MedTech Program Aims to Develop Neurological Treatment Tech
    • Formula Plastics Appoints Bill Gerard as President
    • First Patient Undergoes Kidney Stone Removal Using MONARCH Platform
    • Michael Duqette Named COO at Producto Group
    View Breaking News >
    CURRENT ISSUE

    January/February 2023

    • Struggling Suppliers in Electronics Manufacturing Services (EMS)
    • Machining & Laser Processing Have Huge Parts to Play
    • Medtech R&D Teams Must Be Creative & Resilient to Survive
    • Medtronic Neuromodulation President, Nnamdi Njoku, Interview
    • 6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    ADM Expands Production to Meet Demand for Probiotics
    Wiley’s Finest Debuts Peak DHA Featuring 600 mg of DHA and 300 mg of EPA
    FDA to Allow Qualified CVD Risk Reduction Claim for Cocoa Flavanols in High Flavanol Cocoa Powder
    Coatings World

    Latest Breaking News From Coatings World

    Personnel Changes at BASF
    Dr. Kurt Wood to Deliver Mattiello Memorial Lecture at ACA’s 2023 CoatingsTech Conference
    hubergroup Chemicals to Debut at the European Coatings Show
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Konica Minolta Introduces Mobile X-Ray Systems to Latin America
    NIH MedTech Program Aims to Develop Neurological Treatment Tech
    Formula Plastics Appoints Bill Gerard as President
    Contract Pharma

    Latest Breaking News From Contract Pharma

    ValiRx Signs Lease Deal with Nottingham Laboratories
    Civica Partners with Ypsomed for Insulin Injection Pen
    Charles River Laboratories Completes the Acquisition of SAMDI Tech
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Tree Hut Introduces Body Wash Line
    Zara Introduces Mini Artists—Beauty Products for Kids
    L’Oréal USA Taps Stephanie Kramer as Chief Human Resources Officer
    Happi

    Latest Breaking News From Happi

    FTC Extends Public Comment Period on Potential Updates to Green Guides
    Arm & Hammer Taps Dave & Jenny Marrs, TikTokers for Budget-Centered 'Give It The Hammer' Campaign
    Meaningful Beauty Age-Proof Hair Care System Now Available on Amazon
    Ink World

    Latest Breaking News From Ink World

    Siegwerk, Wildplastic, TU-Hamburg Partner on Deinking
    Brilliant Group and Terra Firm Launch Partnership
    hubergroup Chemicals Debuts at the European Coatings Show
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    The Oldham Group names Doug McClure technical sales rep
    Siegwerk partnership aims to improve plastic waste recyclability
    CELAB-Europe launches new web hub for liner recyclers
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Hospeco Offers TaskBrand Prep-Paint-Finish Wiping System
    Toray to Expand PPS Production in Korea
    Masque Bar Launches Compostable Sheet Masks
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OSSIO Introduces Non-Permanent Compression Staple
    Dennis Jones Joins Intelivation Technologies as Manufacturing VP
    Jury Convicts Chiropractor, Orthopedic Surgeon in $31M Fraud Scheme
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Zebra Technologies Extends Partnership with the NFL
    OE-A at LOPEC – Printed Electronics Up Close
    Monthly Recap: LG OLED, Avery Dennison and JOLED Top This Month’s Stories

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login